Ariel is a health technology company seamlessly integrating complex genetics into clinical decision-making, empowering doctors and patients to prevent, mitigate or even reverse disease progression.
Ariel’s initial focus is pancreatic diseases including pancreatitis, diabetes and pancreatic cancer. ArielDx® Pancreatitis is Ariel’s proprietary multi-gene DNA sequencing panel that identifies combinations of genetic mechanisms likely driving the disease. A comprehensive interpretation of the genetic data is provided in the context of each patient’s current symptoms, biomarkers and health history. Ariel’s technologies are leading the paradigm shift from single-gene (Mendelian) genetics to complex gene-to-gene interactions and the integration of lifestyle and environmental factors to provide a more comprehensive view of disease trajectory and precise therapeutic options.
ADVANCE®, Ariel’s Enterprise Software System, enables patient-specific treatment decisions to be based on the most advanced insights into systems biology, evidence-based medicine, genetic linkages and domain expertise. This has created a novel and scalable solution that enables clinicians and researchers to identify and diagnose the underlying biological causes of symptoms and move beyond diagnosing and treating the general symptoms.